Neurogene (NGNE) Receives a Buy from LifeSci Capital
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Neurogene (NGNE) with a $65.00 price target, citing his strong track record in the healthcare sector. Additionally, Stifel Nicolaus previously issued a Buy rating on NGNE with a $46.00 target. The report also noted TipRanks' launch of the RANK ETF, which tracks large U.S. companies based on analyst momentum data.
In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Neurogene, with a price target of $65.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Dolezal covers the Healthcare sector, focusing on stocks such as Neurogene, Oculis Holding, and Ibio. According to TipRanks, Dolezal has an average return of 16.3% and a 44.34% success rate on recommended stocks.
In a report released on July 6, Stifel Nicolaus also maintained a Buy rating on the stock with a $46.00 price target.